Preclinical AML studies showed palbociclib plus venetoclax produced stronger, more durable anti‑leukemia activity than venetoclax alone and may overcome resistance.

Registered investment advisors (RIAs) in the U.S. face a new anti-money laundering (AML) reality. Starting January 1, 2026 (now potentially delayed until January 1, 2028), RIAs will be required to ...

A detailed to-do list for SEC-registered firms to build a foundation for compliant and effective anti-money laundering ...

The brokerage industry regulator cited gaps in surveillance, customer due diligence, and red-flag escalation across the ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia ...

– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers – SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today ...

In financial institutions across the United States, there’s a reflex that’s become almost ritual. When a regulator walks in, or a board member asks whether the AML program is working, the answer is ...

Two of the largest organizations representing investment advisers and asset managers are voicing support for a federal proposal to postpone new anti-money laundering requirements for RIAs, while ...